New biomarker may predict sepsis death risk
NCT ID NCT07356739
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study examined whether levels of Phoenixin-14, a natural molecule with anti-inflammatory effects, can predict which sepsis patients in the ICU are most likely to die. Researchers measured Phoenixin-14 in the blood of 77 adults with septic shock and compared it to standard markers like CRP and procalcitonin. The goal was to see if Phoenixin-14 could serve as a better early warning sign for doctors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If Phoenixin-14 proves to be a reliable marker, it could help doctors better predict which sepsis patients are at highest risk of dying, leading to more timely and aggressive treatment.
What could go wrong
This is a small, observational study (77 people) that only looked at a single ICU. The findings need to be confirmed in larger, more diverse groups before they can be used in practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS - TO REDUCE MORTALITY IN THE INTENSIVE CARE UNIT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Firat University Hospital
Elâzığ, 23100, Turkey (Türkiye)